Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Core Viewpoint - Predictive Oncology Inc. has announced a registered direct offering of 363,336 shares of common stock at a price of $1.50 per share, aiming to raise approximately $545,004 before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about February 19, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. - The net proceeds from the offering will be used for working capital and general corporate purposes [2]. Group 2: Regulatory Information - The shares are being offered under a "shelf" registration statement on Form S-3, which was declared effective by the SEC on May 21, 2024 [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC [3]. Group 3: Company Overview - Predictive Oncology is focused on AI-driven drug discovery and biologics, utilizing its AI platform, PEDAL, which predicts with 92% accuracy the response of tumor samples to drug compounds [5]. - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [5]. - Predictive Oncology is headquartered in Pittsburgh, PA [5].